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Abstract 
 
 
 
 
 
 
 
Nail psoriasis affects a large number of patients with psoriasis and has a major 
psychosocial impact. Furthermore, it may be regarded as a predictor of more severe 
forms of psoriasis and early sign of psoriatic arthritis. The clinical presentations 
vary depending on the structure affected (nail matrix or nail bed), the nail lesions 
may range from minor to severe, but they are not specific. Treatment is a challenge, 
in most cases the lesions being resistant to therapy.  
We present a rare case of psoriasis with nail onset in a 59-year-old woman. The 
nail involvement confined to the fingernails was severe, with significant 
impairment of the patient’s quality of life. Conventional therapies failed to improve 
the nail lesions, but a marked improvement was achieved under etanercept therapy. 
 
 
Acne conglobata is a rare, severe form of acne vulgaris characterized by the presence of comedones, 
papules, pustules, nodules and sometimes hematic or meliceric crusts, located on the face, trunk, neck, arms 
and buttocks.  
 
Case Report 
We report the case of a 16 year old Caucasian female patient from the urban area who addressed our 
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Introduction 
Psoriasis is a chronic immune-mediated disorder 
affecting about 2% of the general population. The 
pathogenic mechanisms involved in the development of 
psoriasis lesions are related to the activation of the 
immune system, which leads to the release of 
proinflammatory cytokines, such as TNF alpha, IL17, 
12, 23, etc. These mediators of inflammation stimulate 
processes such as excessive keratinocyte proliferation 
and angiogenesis, promoting the occurrence of psoriasis 
lesions (1, 2).  
Most patients with psoriasis develop nail lesions 
during the course of the disease, the prevalence of nail 
psoriasis among patients with psoriasis ranging between 
10 and 78%, with a mild male predominance (3). 
Approximately 1-5% of patients present nail lesions 
without skin manifestations (4). However, studies have 
shown that many patients who initially had only nail 
involvement developed skin or joint lesions later (5). 
Nail psoriasis involves the fingernails more 
frequently than the toenails (3). Clinical signs vary 
depending on the structure affected. If the lesions are 
confined to the nail matrix, pitting (cupuliform 
depressions), leukonychia, red spots in the lunula, or nail 
crumbling may occur. Nail bed lesions lead to 
onycholysis, subungual hyperkeratosis, splinter 
hemorrhages, oil drop discoloration, and nail thickening. 
Nail pitting is the most common sign encountered in nail 
psoriasis (6-8). These changes are not specific and may 
also occur in other disorders (9).   
NAPSI (spell out the first time?) is the most 
commonly used index for assessing the severity of nail 
psoriasis. The method involves the division of the nail 
into four quadrants by drawing imaginary lines (a 
vertical and a horizontal line) and the evaluation of the 
matrix and nail bed lesions in each quadrant (3, 9). 
Treatment is difficult due to the low penetration of 
topical treatments in the nail, the pathologic changes 
further contributing to this problem. As a result, 
systemic therapy is often necessary (10). 
 
Case Report 
A 59-year-old woman was admitted to our clinic for 
nail changes and erythemato-squamous lesions located 
on the tips of her fingers. She stated that the first nail 
changes had started six months earlier and shortly 
afterwards, the skin lesions appeared on her fingers. The 
patient addressed a dermatologist who performed a 
mycological examination that was negative and a skin 
biopsy that established the diagnosis of dyshidrotic 
eczema. Keratolytics and topical corticoids were 
prescribed. The anamnesis revealed that her father had 
psoriasis vulgaris. The patient had no relevant history of 
medical or surgical conditions.  
At the time of presentation to our clinic, the physical 
examination revealed hyperkeratotic nails, with a brown-
yellowish appearance and subungual deposit, painful on 
palpation. Erythemato-squamous lesions, moderately 
pruritic, localized especially on the tips of her fingers, 
were also observed (Figure 1).  
 
  
Figure 1. Hyperkeratotic nails, with a brown-yellow 
appearance and subungual deposit, erythemato-
squamous lesions, localized especially on the tips of 
her fingers 
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The toenails were not involved. Otherwise the 
clinical examination was normal. Laboratory 
investigations did not show any significant abnormality.  
The main differential diagnoses included skin 
conditions associated with nail involvement such as 
palmar eczema, psoriasis vulgaris, lichen planus, and 
alopecia areata. We established the presumptive 
diagnosis of psoriasis vulgaris, given her positive family 
history and clinical examination. We decided to perform 
another biopsy, but the result was inconclusive. We 
initiated treatment with acitretin, as many studies have 
demonstrated a beneficial effect on subungual 
hyperkeratosis and multiple nail involvement.   
After 2 months, well defined erythemato-squamous, 
slightly pruritic lesions occurred predominantly on her 
lower limbs. A biopsy from her left calf was taken, 
confirming the diagnosis of psoriasis vulgaris. The 
histopathologic examination showed parakeratosis, 
epidermal micro-abscesses with neutrophils, acanthosis 
and papillomatosis; in the papillary dermis a dense 
lymphocytic infiltrate predominantly disposed 
perivasculary was noticed. Regarding the nails’ 
appearance, no satisfactory results were observed after 
the treatment with acitretin (Figure 2).  
 
 
 
Figure 2. The clinical aspect after 8 weeks of treatment 
with acitretin 
Therefore we decided to stop acitretin and start 
methotrexate. After 6 months, the clinical evaluation 
revealed extensive erythemato-squamous lesions and a 
modest relief of nail lesions. We considered the 
initiation of the biological therapy. PASI score was 24.8, 
DLQI score 24, and NAPSI score72. Meeting the 
required criteria, the patient was started on etanercept. 
The evolution was rapid and favorable, a 75% 
improvement in PASI score was observed after six 
months of treatment. After 8 months of treatment, PASI 
score was 5, DLQI score 5, and NAPSIscore 32 
(Figurek3). 
 
 
Figure 3. The clinical aspect after 8 month of etanercept 
therapy 
Discussion 
It seems that nail involvement in psoriasis is much 
more common than previously thought. Studies have 
shown that nail psoriasis is positively associated with 
both duration and severity of the disease (4, 11). 
Furthermore numerous studies have revealed a strong 
correlation between nail psoriasis and psoriatic arthritis; 
63-83% of the patients with psoriatic arthritis present 
nail changes (12). Some authors have suggested that nail 
psoriasis could be considered a predictor of the 
development of psoriatic arthritis (13). In the presented 
case, the patient had not developed joint lesions yet.  
Nail psoriasis has a significant impact on the 
patient’s quality of life, in some cases interfering even 
with the simplest daily activities (10). In a large study, a 
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questionnaire was applied to 1,728 subjects with 
psoriasis; 1,379 of them had nail lesions, with 
involvement of both finger and toenails. Regarding 
patients with nail lesions, 93% felt a significant cosmetic 
handicap, 60% reported interferences with their daily 
and professional activities, and 51.8%complained of 
pain (14). In the study by Klaasen (15), the impact on 
the quality of life of patients with nail psoriasis was 
assessed using DLQI and NPQ10, with higher scores 
among women obtained. Psoriasis had a significant 
impact on the quality of life, with results similar to those 
obtained in patients with cardiovascular disease, 
diabetes, or depression (15). In our case, the patient’s 
quality of life was dramatically reduced, the disease 
interfering with the simplest daily activities. In addition, 
the patient had a tendency toward social isolation. 
In a recent study, a positive family history of 
psoriasis was more common in the case of those with 
nail lesions compared to those without nail lesions 
(53.7% vs. 42.8%). Furthermore, a significant 
percentage of those with nail lesions had an early onset 
of psoriasis (under the age of 40 years) (4). Regana et al. 
have revealed a positive relationship between the 
severity of nail lesions and being 65 years or older, as 
well as a positive family history of psoriasis or type of 
psoriasis, most of whom suffered from moderate-severe 
psoriasis (16). Our patient had a positive family history, 
her father suffering from psoriasis. 
Our case illustrates the difficulty in treating nail 
psoriasis, multiple therapies being often necessary until a 
satisfactory response is achieved. In mild and moderate 
forms of nail psoriasis, local therapy is the first choice. 
Systemic therapy is recommended when nail psoriasis is 
associated with extensive cutaneous psoriasis lesions, if 
the lesions are severe or involve several nails (5 out of 
10 or more), and if the disease has a significant impact 
on the patient’s quality of life, interfering with the daily 
activities (6, 17). 
In our case, we opted for acitretin given the 
extensive nail lesions, characterized by an important 
hyperkeratosis, associated with skin lesions on the tip of 
the fingers. Ricerri reported a case of psoriasis in a 73-
year-old patient with severe nail psoriasis involving all 
fingernails and toenails successfully treated with 
acitretin (0.5 mg/kg). He associated urea-based lacquer 
as adjuvant treatment (18). Tosti reported a 41% 
reduction in the NAPSI score among patients treated 
with acitretin, the first improvement in the clinical 
appearance being observed after 4-8 weeks of treatment 
(19). However, acitretin may lead to onycholysis and 
nail fragility, sodoses should beas low as possible (20). 
In our case after 8 weeks of treatment, no satisfactory 
results were observed and further skin lesions developed. 
Thus we cease dacitretin treatment and began 
methotrexate treatment. 
 
Several studies have demonstrated the efficacy of 
methotrexate on nail psoriasis; the favorable results are 
probably based on the drug action on T-lymphocytes (8). 
For example, patients with nail psoriasis who received 
15mg/weekly of methotrexate showed a reduction in the 
NAPSI score of43.3% after 24 weeks of treatment. In 
the same study,patients treated with cyclosporine 
showed a 37% mean improvement in the NAPSI score 
(21). However, in other studies cyclosporine was 
superior to methotrexate (16). In our case, six months 
after starting treatment with methotrexate, results were 
not satisfactory and we decided to initiate therapy with a 
biological agent. Biological agents have proven their 
efficacy in both cutaneous and nail lesions. Infliximab, 
adalimumab and etanercept are the most studied 
treatments; we decided to give our patient etanercept. 
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Regana et al. have shown that classical treatments 
(methotrexate, cyclosporine) lead to results comparable 
to those obtained using biological therapy (16). 
However, it should be noted that classical therapies must 
be administered over longer periods of time to achieve 
good results (16, 22).  
Etanercept is a genetically engineered fusion protein 
that combines the constant portion of IgG, the Fc 
fragment containing the CH2 and CH3 constant regions, 
with two p75 receptors of TNFR-2 (23). Etanercept 
binds soluble TNFα and TNFβ (24). A randomized study 
(CRYSTAL) of 564 patients with moderate-severe 
psoriasis associated with nail lesions receiving 
etanercept showed a decrease in the NAPSI score of 
28.9% at 12 weeks and 51% at 54 weeks of treatment 
(25). The efficacy of etanercept in nail psoriasis has also 
been supported by other studies (7, 26, 27). In our case, 
there was a rapid response to etanercept with a 
significant reduction in the NAPSI score. 
Bardazzi et al. concluded that adalimumab, 
infliximab, ustekinumab and etanercept exhibit similar 
efficacy in the treatment of nail psoriasis. They also 
postulated that patients with nail lesions reach PASI 75 
slower than those without nail involvement (28). 
 
Conclusions 
We present a case of psoriasis vulgaris with nail 
onset, characterized by severe nail lesions and a 
significant impact on the patient’s quality of life, with a 
marked improvement following the treatment with 
etanercept and poor response to classical therapies with 
acitretin and methotrexate. Nail lesions are common 
among psoriasis patients and are associated with a 
significant psychosocial impact. Treatment often 
remains a significant challenge. 
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